Mark G. Fromhold
Corporate Officer/Principal at Koronis Pharmaceuticals, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Donald J. Elmer | M | - |
Koronis Pharmaceuticals, Inc.
 Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Jeffrey J. Miller | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Graham K. Crooke | M | 65 |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| George R. Painter | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| David A. Krekel | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
| Richard V. McCloskey | M | - |
Koronis Pharmaceuticals, Inc.
Koronis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Koronis Pharmaceuticals, Inc. develops antiviral therapeutics based on viral decay acceleration. Its therapeutics are designed to inhibit a specific viral protein or enzyme, drugs based on VDA are designed to provoke the rapid decay of the targeted virus by further increasing its naturally high rate of mutation. The company was founded by Richard Daifuku in 1998 and is headquartered in Seattle, WA. | - |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 6 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark G. Fromhold
- Personal Network
